RT Journal Article
SR Electronic
T1 Shotgun mass spectrometry-based lipid profiling identifies and distinguishes between chronic inflammatory diseases
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.08.21252659
DO 10.1101/2021.03.08.21252659
A1 Matthiesen, Rune
A1 Lauber, Chris
A1 Sampaio, Julio L.
A1 Domingues, Neuza
A1 Alves, Liliana
A1 Gerl, Mathias J.
A1 Almeida, Manuel S.
A1 Rodrigues, Gustavo
A1 Gonçalves, Pedro Araújo
A1 Ferreira, Jorge
A1 Borbinha, Cláudia
A1 Marto, João Pedro
A1 Neves, Marisa
A1 Batista, Frederico
A1 Viana-Baptista, Miguel
A1 Alves, Jose
A1 Simons, Kai
A1 Vaz, Winchil L. C.
A1 Vieira, Otilia V.
YR 2021
UL http://medrxiv.org/content/early/2021/03/09/2021.03.08.21252659.abstract
AB Background Inflammation impacts several acute and chronic diseases causing localized stress and cell death, releasing tissue-specific lipids into the circulation from inflamed cells and tissues. The plasma lipidome may be expected to reflect the type of inflammation and the specific cells and tissues involved. However, deep lipid profiles of major chronic inflammatory diseases have not been compared.Methods We compare the plasma lipidomes of patients suffering from two etiologically distinct chronic inflammatory diseases, atherosclerosis-related cardiovascular disease (CVD) including ischemic stroke (IS), and systemic lupus erythematosus (SLE), to each other and to age-matched controls. The controls had never suffered from any of these diseases. Blood plasma lipidomes were screened by a top-down shotgun MS-based analysis without liquid chromatographic separation. Lipid profiling based on MS was performed on a cohort of 427 individuals. The cohort constitutes 85 controls (control), 217 with cardiovascular disease (further classified into CVD 1-5), 21 ischemic stroke patients (IS), and 104 patients suffering from systemic lupus erythematosis (SLE). 596 lipids were profiled which were quality filtered for further evaluation and determination of potential biomarkers. Lipidomes were compared by linear regression and evaluated by machine learning classifiers.Results Machine learning classifiers based on the plasma lipidomes of patients suffering from CVD and SLE allowed clear distinction of these two chronic inflammatory diseases from each other and from healthy age-matched controls and body mass index (BMI). We demonstrate convincing evidence for the capability of lipidomics to separate the studied chronic and inflammatory diseases from controls based on independent validation test set classification performance (CVD vs control - Sensitivity: 0.90, Specificity: 0.98; IS vs control - Sensitivity: 1.0, Specificity: 1.0; SLE vs control – Sensitivity: 1, Specificity: 0.88) and from each other (SLE vs CVD □ Sensitivity: 0.91, Specificity: 1). Preliminary linear discriminant analysis plots using all data clearly separated the clinical groups from each other and from the controls. In addition, CVD severities, as classified into five clinical groups, were partially separable by linear discriminant analysis. Notably, significantly dysregulated lipids between pathological groups versus control displayed a reverse lipid regulation pattern compared to statin treated controls versus non treated controls.Conclusion Dysregulation of the plasma lipidome is characteristic of chronic inflammatory diseases. Lipid profiling accurately identifies the diseases and in the case of CVD also identifies sub-classes. Dysregulated lipids are partially but not fully counterbalanced by statin treatment.Competing Interest StatementKS is CEO and shareholder of of Lipotype GmbH. CL and MG are employees of Lipotype GmbH. Clinical TrialNCT04786431Funding StatementThis work was supported by PTDC/MED-PAT/29395/2017 financially supported by Fundacao para a Ciencia e a Tecnologia (FCT), through national funds and cofunded by FEDER under the PT2020 Partnership. ND was a holder of PhD fellowship from the FCT (Ref. SFRH/BD/51877/2012), attributed 10 by Inter-University Doctoral Programme in Ageing and Chronic Disease (PhDOC). LA was a holder of a FCT PhD fellowship (PD/BD/114254/2016), attributed by the ProRegem Doctoral Programme in 2016.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Plasma was obtained from all donors after explaining the purpose and obtaining written informed-consent from them or their legal representatives. The entire process was approved by the Ethical Review Board of the Faculty of Medicine of the New University of Lisbon and the Ethics Committee for Health of the Centro Hospitalar de Lisboa Ocidental, that includes the Hospital Santa Cruz, the Hospital Egas Moniz and Hospital Sao Francisco Xavier, and the Ethics Committee for Health of the Hospital Fernando Fonseca. All experiments were performed in accordance with the guidelines and regulations.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript will be available